ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
77 hedge funds and large institutions have $1.28B invested in Adaptimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.74% less ownership
Funds ownership: 14.93% → 14.19% (-0.74%)
49% less call options, than puts
Call options by funds: $5.46M | Put options by funds: $10.7M
Holders
77
Holding in Top 10
4
Calls
$5.46M
Puts
$10.7M
Top Buyers
| 1 | +$100M | |
| 2 | +$45.5M | |
| 3 | +$29.9M | |
| 4 |
RI
RTW Investments
New York
|
+$26M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25M |
Top Sellers
| 1 | -$6.87M | |
| 2 | -$2.04M | |
| 3 | -$446K | |
| 4 |
WM
WS Management
Jacksonville,
Florida
|
-$209K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$104K |